Free TB Care: New Center Opens in Lille, France
- A new tuberculosis (TB) treatment and prevention center, the CLAT Grand Lille, opened its doors at the CHU de Lille (Lille University Hospital) on January 5, 2026.
- Located at the Albert Calmette Hospital (1, boulevard du professeur Jules Leclercq), the CLAT Grand Lille provides what is described as “complete care” for tuberculosis.
- The CLAT Grand Lille’s service area encompasses the cities of Lille, Tourcoing, Roubaix, Haubourdin, and Villeneuve d’Ascq, ensuring coordinated care for patients throughout the region.
A new tuberculosis (TB) treatment and prevention center, the CLAT Grand Lille, opened its doors at the CHU de Lille (Lille University Hospital) on . The center offers free, by-appointment services for TB prevention, screening, monitoring, and treatment, serving a significant portion of the Lille metropolitan area in northern France.
Comprehensive, Free TB Care in Lille
Located at the Albert Calmette Hospital (1, boulevard du professeur Jules Leclercq), the CLAT Grand Lille provides what is described as “complete care” for tuberculosis. The center is accredited by the Hauts-de-France Regional Health Agency (ARS) and offers a guided care pathway led by healthcare professionals. This includes, when necessary, medical imaging and biological sample collection.
The CLAT Grand Lille’s service area encompasses the cities of Lille, Tourcoing, Roubaix, Haubourdin, and Villeneuve d’Ascq, ensuring coordinated care for patients throughout the region. This builds upon an existing network coordinated by the hospital center in Tourcoing, with the Tourcoing CLAT also serving as a key component.
Tuberculosis remains a significant global health concern, though often underappreciated in developed nations. While advancements in treatment have been made, drug-resistant strains pose a continuing challenge. The availability of accessible, free care, as offered by the CLAT Grand Lille, is crucial for effective disease control and prevention.
The center’s role extends beyond direct patient care. In close collaboration with healthcare professionals and Santé Publique France (the French public health agency), the network of CLAT centers contributes to the epidemiological surveillance of tuberculosis. This includes mandatory reporting of TB cases and tracking treatment outcomes, vital for understanding disease trends and informing public health strategies.
Appointments at the CLAT Grand Lille are free and available by calling or emailing [email protected]. The center is open Monday through Friday, from 8:30 AM to 5:30 PM.
Recent research conducted in Lille has contributed to advancements in TB treatment. A study at the University of Lille and the Institut Pasteur in Lille, initiated in , led to the discovery of a method to overcome resistance developed by certain strains of tuberculosis bacteria, specifically against ethionamide, a key treatment drug. The resulting treatment, BVL-GSK098, is currently undergoing Phase 1 clinical trials – the first stage of human testing – after showing promise in laboratory settings. This represents a novel approach, as This proves the first time a mechanism bypassing bacterial resistance has been the subject of a clinical trial.
This research, led by Doctor Alain Baulard from the Lille Infection and Immunity Center (CIIL), and Professors Nicolas Willand and Benoît Deprez from the Medicines and Molecules for Action on Living Systems research unit (M2SV), offers hope for improved treatment outcomes and addresses the broader challenge of antibiotic resistance. The development of BVL-GSK098 aims to boost the efficacy of ethionamide by circumventing the bacteria’s resistance mechanisms.
the TB Alliance highlights the economic benefits of newer TB treatments like BPaL/M, which costs less than $2 per day. The organization emphasizes that the majority of cost savings stem from shorter and simpler treatment regimens, reducing the burden on healthcare systems and enabling expanded access to care, particularly in resource-limited settings. The Alliance estimates that BPaL/M will save health systems nearly $1.3 billion globally over the first 15 years of its approval, and will result in over 5 million additional healthy years of life for those treated.
The opening of the CLAT Grand Lille and ongoing research efforts in the region underscore France’s commitment to combating tuberculosis and improving public health. Accessible, free care combined with innovative research represents a multi-faceted approach to tackling this persistent global health threat.